Literature DB >> 26719344

Lidocaine response rate in aEEG-confirmed neonatal seizures: Retrospective study of 413 full-term and preterm infants.

Lauren C Weeke1, Mona C Toet1, Linda G M van Rooij1, Floris Groenendaal1, Geraldine B Boylan2, Ronit M Pressler3, Lena Hellström-Westas4, Marcel P H van den Broek5, Linda S de Vries1.   

Abstract

OBJECTIVE: To investigate the seizure response rate to lidocaine in a large cohort of infants who received lidocaine as second- or third-line antiepileptic drug (AED) for neonatal seizures.
METHODS: Full-term (n = 319) and preterm (n = 94) infants, who received lidocaine for neonatal seizures confirmed on amplitude-integrated EEG (aEEG), were studied retrospectively (January 1992-December 2012). Based on aEEG findings, the response was defined as good (>4 h no seizures, no need for rescue medication); intermediate (0-2 h no seizures, but rescue medication needed after 2-4 h); or no clear response (rescue medication needed <2 h).
RESULTS: Lidocaine had a good or intermediate effect in 71.4%. The response rate was significantly lower in preterm (55.3%) than in full-term infants (76.1%, p < 0.001). In full-term infants the response to lidocaine was significantly better than midazolam as second-line AED (21.4% vs. 12.7%, p = 0.049), and there was a trend for a higher response rate as third-line AED (67.6% vs. 57%, p = 0.086). Both lidocaine and midazolam had a higher response rate as third-line AED than as second-line AED (p < 0.001). Factors associated with a good response to lidocaine were the following: higher gestational age, longer time between start of first seizure and administration of lidocaine, lidocaine as third-line AED, use of new lidocaine regimens, diagnosis of stroke, use of digital aEEG, and hypothermia. Multivariable analysis of seizure response to lidocaine included lidocaine as second- or third-line AED and seizure etiology. SIGNIFICANCE: Seizure response to lidocaine was seen in ~70%. The response rate was influenced by gestational age, underlying etiology, and timing of administration. Lidocaine had a significantly higher response rate than midazolam as second-line AED, and there was a trend for a higher response rate as third-line AED. Both lidocaine and midazolam had a higher response rate as third-line compared to second-line AED, which could be due to a pharmacologic synergistic mechanism between the two drugs. Wiley Periodicals, Inc.
© 2015 International League Against Epilepsy.

Entities:  

Keywords:  Antiepileptic drugs; Lidocaine; Midazolam; Neonatal seizures; Response rate

Mesh:

Substances:

Year:  2015        PMID: 26719344     DOI: 10.1111/epi.13286

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  13 in total

Review 1.  Pharmacotherapy for Seizures in Neonates with Hypoxic Ischemic Encephalopathy.

Authors:  Elissa Yozawitz; Arthur Stacey; Ronit M Pressler
Journal:  Paediatr Drugs       Date:  2017-12       Impact factor: 3.022

Review 2.  Acute symptomatic seizures in term neonates: Etiologies and treatments.

Authors:  Janet S Soul
Journal:  Semin Fetal Neonatal Med       Date:  2018-02-06       Impact factor: 3.926

Review 3.  Recent Advances in Neonatal Seizures.

Authors:  Tristan T Sands; Tiffani L McDonough
Journal:  Curr Neurol Neurosci Rep       Date:  2016-10       Impact factor: 5.081

4.  Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia.

Authors:  Laurent M A Favié; Floris Groenendaal; Marcel P H van den Broek; Carin M A Rademaker; Timo R de Haan; Henrica L M van Straaten; Peter H Dijk; Arno van Heijst; Sinno H P Simons; Koen P Dijkman; Monique Rijken; Inge A Zonnenberg; Filip Cools; Alexandra Zecic; Johanna H van der Lee; Debbie H G M Nuytemans; Frank van Bel; Toine C G Egberts; Alwin D R Huitema
Journal:  Neonatology       Date:  2019-06-28       Impact factor: 4.035

Review 5.  Neuroprotective therapies in the NICU in term infants: present and future.

Authors:  Eleanor J Molloy; Mohamed El-Dib; Sandra E Juul; Manon Benders; Fernando Gonzalez; Cynthia Bearer; Yvonne W Wu; Nicola J Robertson; Tim Hurley; Aoife Branagan; C Michael Cotten; Sidhartha Tan; Abbot Laptook; Topun Austin; Khorshid Mohammad; Elizabeth Rogers; Karen Luyt; Sonia Bonifacio; Janet S Soul; Alistair J Gunn
Journal:  Pediatr Res       Date:  2022-10-04       Impact factor: 3.953

Review 6.  Pharmacotherapy for Neonatal Seizures: Current Knowledge and Future Perspectives.

Authors:  Maria D Donovan; Brendan T Griffin; Liudmila Kharoshankaya; John F Cryan; Geraldine B Boylan
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 7.  Novel Therapeutics for Neonatal Seizures.

Authors:  Julie M Ziobro; Krista Eschbach; Renée A Shellhaas
Journal:  Neurotherapeutics       Date:  2021-08-12       Impact factor: 6.088

8.  Marked improvement in febrile infection-related epilepsy syndrome after lidocaine plus MgSO4 treatment in a 12-year-old girl.

Authors:  I-Ching Chou; Huan-Cheng Lai; Fuu-Jen Tsai; Yu-Tzu Chang; Sheng-Shing Lin; Syuan-Yu Hong; Inn-Chi Lee
Journal:  Epilepsy Behav Case Rep       Date:  2016-06-02

9.  Rhythmic EEG patterns in extremely preterm infants: Classification and association with brain injury and outcome.

Authors:  Lauren C Weeke; Inge M van Ooijen; Floris Groenendaal; Alexander C van Huffelen; Ingrid C van Haastert; Carolien van Stam; Manon J Benders; Mona C Toet; Lena Hellström-Westas; Linda S de Vries
Journal:  Clin Neurophysiol       Date:  2017-10-03       Impact factor: 3.708

10.  A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures.

Authors:  Janet S Soul; Ann M Bergin; Christian Stopp; Breda Hayes; Avantika Singh; Carmen R Fortuno; Deirdre O'Reilly; Kalpathy Krishnamoorthy; Frances E Jensen; Valerie Rofeberg; Min Dong; Alexander A Vinks; David Wypij; Kevin J Staley
Journal:  Ann Neurol       Date:  2020-12-03       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.